玻璃体注射雷珠单抗治疗早产儿视网膜病变效果观察
|
摘要
目的:探讨玻璃体注射雷珠单抗治疗早产儿视网膜病变(ROP)效果。方法:回顾性分析ROP患儿90例,依据治疗方式将给予视网膜光凝治疗患儿纳入对照组(n=43),行玻璃体注射雷珠单抗治疗患儿纳入观察组(n=47),比较2组患儿临床疗效。结果:观察组新生儿血管消退率(97.87%)高于对照组(74.42%),血管扩张迂曲好转率(96.81%)高于对照组(68.60%),视网膜增生发生率(1.06%)低于对照组(11.63%)(P<0.05);治疗后,观察组谷氨酸低于对照组[(75.30±21.78) mmol/L vs(89.87±19.56) mmol/L],血管内皮生长因子(VEGF)水平低于对照组[(352.44±46.30) ng/L vs(372.82±49.50) ng/L],胰岛素样生长因子-1(IGF-1)高于对照组[(40.65±9.33) ng/L vs (34.70±7.31) ng/L](P<0.05);观察组治疗有效率(89.36%)高于对照组(65.12%)(P<0.05);观察组并发症发生率(3.19%)低于对照组(11.63%)(P<0.05)。结论:玻璃体注射雷珠单抗治疗ROP,可有效改善患儿血管造影表现和血清指标,效果显著,安全性较高。
Objective:To explore the effects of vitreous injection of ranibizumab in the treatment of retinopathy of prematurity(ROP).Methods: 90 patients with ROP diagnosed in our hospital were retrospectively analyzed. According to the treatment methods, children patients with retinal photocoagulation were included in control group(n=43), and children patients with intravitreal injection of ranibizumab were included in observation group(n=47). The clinical efficacy was compared between the two groups. Results: The effective rate of treatment in observation group was higher than that in control group(89.36% vs 65.12%)(P <0.05). The neonatal vascular regression rate in observation group was higher than that in control group(97.87% vs 74.42%), and the improvement rate of vasodilatation tortuosity was higher than that in control group(96.81% vs 68.60%), and the incidence rate of retinal hyperplasia was lower than that in control group(1.06% vs11.63%)(P <0.05). The levels of glutamate and vascular endothelial growth factor(VEGF) in observation group were lower than those in control group, and insulin-like growth factor-1(IGF-1) level was higher than that in control group(P<0.05). The incidence rate of complications in observation group was lower than that in control group(3.19% vs 11.63%)(P <0.05). Conclusion: Intravitreal injection of ranibizumab for the treatment of ROP can effectively improve the angiographic performance and serum index of children patients, and it has significant effects and high safety.
Objective:To explore the effects of vitreous injection of ranibizumab in the treatment of retinopathy of prematurity(ROP).Methods: 90 patients with ROP diagnosed in our hospital were retrospectively analyzed. According to the treatment methods, children patients with retinal photocoagulation were included in control group(n=43), and children patients with intravitreal injection of ranibizumab were included in observation group(n=47). The clinical efficacy was compared between the two groups. Results: The effective rate of treatment in observation group was higher than that in control group(89.36% vs 65.12%)(P <0.05). The neonatal vascular regression rate in observation group was higher than that in control group(97.87% vs 74.42%), and the improvement rate of vasodilatation tortuosity was higher than that in control group(96.81% vs 68.60%), and the incidence rate of retinal hyperplasia was lower than that in control group(1.06% vs11.63%)(P <0.05). The levels of glutamate and vascular endothelial growth factor(VEGF) in observation group were lower than those in control group, and insulin-like growth factor-1(IGF-1) level was higher than that in control group(P<0.05). The incidence rate of complications in observation group was lower than that in control group(3.19% vs 11.63%)(P <0.05). Conclusion: Intravitreal injection of ranibizumab for the treatment of ROP can effectively improve the angiographic performance and serum index of children patients, and it has significant effects and high safety.
引文
[1]程湧,梁建宏,黎晓新.康柏西普玻璃体腔注射治疗急进性后极部早产儿视网膜病变的疗效观察[J].中华眼底病杂志,2017,33(2):144-147.
[2]王新茹.玻璃体内注射雷珠单抗联合激光光凝治疗早产儿视网膜病变疗效观察[J].眼科新进展,2018,38(2):172-175.
[3]李丹,董宇,LIDan,等.早产儿视网膜病变发病基础及抗VEGF药物治疗研究进展[J].眼科新进展,2016,36(4):396-400.
[4]李松峰,邓光达,刘敬花,等.玻璃体内注射雷珠单抗治疗早产儿视网膜病变[J].眼科新进展,2016,36(7):655-657.
[5]董丽娟,陈超.雷珠单抗治疗早产儿视网膜病变研究进展[J].中国实用儿科杂志,2016,19(11):874-879.
[6]杨秀梅,何涛,邱岩,等.玻璃体内注射雷珠单抗治疗早产儿视网膜病变疗效观察[J].眼科新进展,2017,37(2):137-140.
[7]刘梅.玻璃体腔注射雷珠单抗治疗早产儿视网膜病变疗效分析[J].中国实用眼科杂志,2017,35(7):718.
[8]Bressler SB, Beaulieu WT, Glassman AR, et al. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab[J].Ophthalmology,2017,124(4):431.
[9]Mataftsi A,Koulali E,Papageorgiou E,et al. Letter to the Editor:Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab[J]. Ophthalmic Surgery Lasers&Imaging Retina,2017,48(5):372-372.
[10]王改琴,高雪辉.早产儿视网膜病变玻璃腔内注射雷珠单抗对患儿VEGF、IGF-1、GLU的影响[J].西北国防医学杂志,2017,22(6):12-16.
[11]陈龙凤,高华顺,王改琴.早产儿视网膜病变玻璃体腔内注射雷珠单抗对患儿血清血管内皮生长因子、胰岛素样生长因子及谷氨酸水平的影响[J].中国妇幼保健,2018,33(2):349-352.
[2]王新茹.玻璃体内注射雷珠单抗联合激光光凝治疗早产儿视网膜病变疗效观察[J].眼科新进展,2018,38(2):172-175.
[3]李丹,董宇,LIDan,等.早产儿视网膜病变发病基础及抗VEGF药物治疗研究进展[J].眼科新进展,2016,36(4):396-400.
[4]李松峰,邓光达,刘敬花,等.玻璃体内注射雷珠单抗治疗早产儿视网膜病变[J].眼科新进展,2016,36(7):655-657.
[5]董丽娟,陈超.雷珠单抗治疗早产儿视网膜病变研究进展[J].中国实用儿科杂志,2016,19(11):874-879.
[6]杨秀梅,何涛,邱岩,等.玻璃体内注射雷珠单抗治疗早产儿视网膜病变疗效观察[J].眼科新进展,2017,37(2):137-140.
[7]刘梅.玻璃体腔注射雷珠单抗治疗早产儿视网膜病变疗效分析[J].中国实用眼科杂志,2017,35(7):718.
[8]Bressler SB, Beaulieu WT, Glassman AR, et al. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab[J].Ophthalmology,2017,124(4):431.
[9]Mataftsi A,Koulali E,Papageorgiou E,et al. Letter to the Editor:Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab[J]. Ophthalmic Surgery Lasers&Imaging Retina,2017,48(5):372-372.
[10]王改琴,高雪辉.早产儿视网膜病变玻璃腔内注射雷珠单抗对患儿VEGF、IGF-1、GLU的影响[J].西北国防医学杂志,2017,22(6):12-16.
[11]陈龙凤,高华顺,王改琴.早产儿视网膜病变玻璃体腔内注射雷珠单抗对患儿血清血管内皮生长因子、胰岛素样生长因子及谷氨酸水平的影响[J].中国妇幼保健,2018,33(2):349-352.